Center Laboratories, Inc. AI Stock Analysis
Center Laboratories, Inc. (4123) AI Stock Analysis
Center Laboratories, Inc.
(TPEx:4123)
The score is held back primarily by weak operating fundamentals: revenue declined 3.1%, gross margins have compressed for three consecutive years, and the headline NT$9.3B profit was almost entirely non-cash and non-operating, with operating cash flow of only NT$27M and negative free cash flow. Technicals reinforce the caution, with the share price below all major moving averages and a negative MACD, although oversold RSI and Stochastic readings hint at potential for a near-term bounce. On the positive side, the balance sheet is conservative and resilient — NT$26.5B of equity, debt-to-equity reduced to 0.18 — and a 6.19% dividend yield offers income appeal, though its durability depends on improved cash generation. A P/E of 24.5 built on one-off gains offers little valuation support. Key watch items are a return to revenue growth, margin stabilization and evidence the core pharmaceutical business can generate sustainable cash.
Center Laboratories, Inc. (4123) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- TWD 21.98B
- Dividend Yield
- 6.15%
- Average Volume (3M)
- 1.62M
- Price to Earnings (P/E)
- 23.8
- Beta (1Y)
- 0.12
- Revenue Growth
- 3.63%
- EPS Growth
- ―
- Country
- TW
- Employees
- 182
- Sector
- General
- Sector Strength
- 55
- Industry
- Drug Manufacturers - Specialty & Generic
Center Laboratories, Inc. Business Overview & Revenue Model
Company Description
Center Laboratories, Inc. operates as a Taiwanese pharmaceutical enterprise, with its primary focus lying in the manufacturing and distribution of various medical products across Taiwan. Beyond its core drug operations, the firm is heavily invested i...
Center Laboratories, Inc. Financial Statement Overview
Summary
A strong balance sheet (score 77) is offset by weak earnings quality (44) and poor cash generation (27). Equity has grown to NT$26.5B with debt-to-equity cut to just 0.18, giving substantial financial flexibility. However, revenue fell 3.1% to NT$1.52B after years of growth, gross margin compressed from 53% in 2022 to 41%, and the headline NT$9.3B profit came almost entirely from non-operating gains rather than the core drug business. Operating cash flow was a near-breakeven NT$27M and free cash flow negative at -NT$181M, meaning the company is not yet self-funding.
Income Statement
44NeutralBalance Sheet
77PositiveCash Flow
27Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Mar 2023 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.66B | 1.52B | 1.62B | 1.39B | 767.72M | 500.11M |
| Gross Profit | 680.07M | 621.26M | 748.95M | 618.09M | 406.27M | 259.66M |
| EBITDA | 12.09B | 11.95B | -232.41M | -765.79M | 232.50M | 2.73B |
| Net Income | 1.02B | 9.32B | -1.10B | -995.42M | -575.62M | 1.82B |
Balance Sheet | ||||||
| Total Assets | 23.97B | 34.63B | 25.54B | 27.00B | 25.19B | 30.44B |
| Cash, Cash Equivalents and Short-Term Investments | 3.85B | 974.21M | 3.23B | 4.55B | 2.56B | 5.09B |
| Total Debt | 4.10B | 4.70B | 6.53B | 5.62B | 3.47B | 5.27B |
| Total Liabilities | 6.81B | 8.14B | 7.48B | 6.79B | 5.94B | 9.35B |
| Stockholders Equity | 17.16B | 26.49B | 18.05B | 19.76B | 19.25B | 18.94B |
Cash Flow | ||||||
| Free Cash Flow | 249.78M | -181.05M | 234.89M | -1.14B | -197.43M | -364.79M |
| Operating Cash Flow | 405.33M | 27.16M | 415.71M | -963.44M | -189.88M | -358.14M |
| Investing Cash Flow | 4.16B | 1.65B | -757.51M | -129.01M | 5.18B | -655.88M |
| Financing Cash Flow | -1.55B | -2.88B | 79.09M | 2.00B | -4.46B | 358.10M |
Center Laboratories, Inc. Peers Comparison
Overall Rating
TW:410579Outperform
TW:662070Outperform- TW:412348Neutral
TW:474342Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| TW:4105 | 79Outperform | TWD 20.44B | 12.48 | ― | 5.48% | 4.54% | -7.38% |
| TW:6620 | 70Outperform | TWD 20.83B | 66.76 | ― | 1.52% | ― | ― |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| TW:4123 | 48Neutral | TWD 22.38B | 23.82 | ― | 6.15% | 3.63% | ― |
| TW:4743 | 42Neutral | TWD 22.59B | -102.60 | ― | ― | 14.79% | 84.54% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| TW:4123 | Center Laboratories, Inc. | 28.40 | -5.05 | -15.09% | |
| TW:4105 | TTY Biopharm Company Limited | 82.10 | 7.54 | 10.12% | |
| TW:4743 | Oneness Biotech Co., Ltd. | 46.25 | -16.55 | -26.35% | |
| TW:6620 | Handa Pharmaceuticals Inc | 136.50 | 16.48 | 13.73% | |
| TW:7686 | A-Top Health Biotech Co., Ltd. | 729.00 | 209.00 | 40.19% | |
| TW:7827 | HanchorBio Inc. | 119.00 | 49.90 | 72.21% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 09, 2026